期刊
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
卷 4, 期 1, 页码 46-53出版社
OXFORD UNIV PRESS
DOI: 10.1093/ehjcvp/pvx018
关键词
Pericarditis; Anakinra; Interleukin-1; Human interleukin-1 receptor antagonist
资金
- Swedish Orphan Biovitrum (Stockholm, Sweden) - National Heart, Lung, and Blood Institute (National Institutes of Health, USA) [NCT02173548, NCT01950299, NCT01936909]
Pericarditis is a debilitating condition that results from profound inflammation of the pericardial tissue. Between 10 and 15% of first episodes of acute pericarditis will be followed by several episodes refractory to conventional treatment. Current standard of care for pericarditis treatment includes high-dose non-steroidal anti-inflammatory drugs, colchicine, and systemic corticosteroids, each associated with potentially severe toxicities and nominal efficacy. Interleukin-1 (IL-1), an apical pro-inflammatory cytokine, plays an important role as an autocrine magnifier of systemic inflammation in pericarditis. Interruption of the IL-1 circuit has been shown to have a favourable risk profile in several disease states. In this review, we discuss the growing body of evidence which supports the use of IL-1 blockade in the treatment of recurrent pericarditis as well as provide practical considerations for the use of IL-1 blockade in clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据